Scarica l'app Stockscreener
878.24
2.09%
-18.76
Dopo l'orario di chiusura:
875.00
-3.24
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive - Law360
Eli Lilly Stock (LLY) Gets a Boost From Latest Trial Results. It Has Nothing to Do with Obesity Drugs - tipranks.com
RICO suit vs. Lilly could reap billions if successful - The Indiana Lawyer
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Judge Advances Lilly Suit Over Online Platforms’ Mounjaro Copies - Bloomberg Law News
Eli Lilly stock price forecast: bears dominate as LLY consolidates near 200-day support - Traders Union
Clark Foundation, Lilly to partner on new downtown basketball court - Indiana Economic Digest
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Jefferies reiterates Buy on Eli Lilly stock, $1,300 target - investing.com
Lilly’s Ebglyss shows four-year efficacy in eczema study - investing.com
Erste Group Bank Raises Eli Lilly's FY2027 Earnings Forecast - National Today
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis - prnewswire.com
AI Models Split on Eli Lilly: Strong Fundamentals, Premium Valuation - tipranks.com
Pensionfund Sabic Buys $1.83M Stake in Eli Lilly - National Today
Pensionfund Sabic Makes New Investment in Eli Lilly and Company - National Today
Institutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!) - The Motley Fool
Bath Savings Trust Co Boosts Stake in Eli Lilly - National Today
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares - Stock Titan
Eli Lilly & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Why is Eli Lilly stock down today? - Traders Union
The Bull Case For Eli Lilly (LLY) Could Change Following Retatrutide Milestone And Governance ShiftLearn Why - simplywall.st
Eli Lilly stock price forecast: consolidation after recovery as LLY holds above long-term support - Traders Union
Eli Lilly's Sustainability in Pharmaceuticals Strategy - Sustainability Magazine
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley - tipranks.com
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer? - Insider Monkey
Assessing Eli Lilly (LLY) Valuation After The Recent Share Price Pullback - simplywall.st
Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com
AI Models Split on Eli Lilly: Strong Growth vs. Premium Valuation - tipranks.com
Spartan Planning & Wealth Management Buys Shares of 1,556 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Dynamic Advisor Solutions LLC - MarketBeat
Biocon To Benefit After Eli Lilly Joins Novo Nordisk To Exit European Insulins Market - NDTV Profit
INNOVENT BIO-Eli Lilly Strategic Collaboration Deal Takes Effect; Rumored Acquisition Intent Not True - AASTOCKS.com
Eli Lilly to phase out select insulin products across Europe by 2027 - MSN
Workforce was region’s secret weapon in winning Eli Lilly | Opinion - PennLive.com
Martin Shkreli Says Silicon Valley's Hottest Health Obsession Is A 'Delusion' - Benzinga
Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study - TipRanks
Barclays Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - tipranks.com
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 - Benzinga
Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order - Fierce Pharma
Eli Lilly (NYSE:LLY) Sees Institutional Activity in Russell 1000 - Kalkine Media
Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform - Insider Monkey
Gradient Investments LLC Buys 19,634 Shares of Eli Lilly and Company $LLY - MarketBeat
Hutchens & Kramer Investment Management Group LLC Sells 3,715 Shares of Eli Lilly and Company $LLY - MarketBeat
Grove Bank & Trust Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by Sarasin & Partners LLP - MarketBeat
Nordea Investment Management AB Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,350 - Moomoo
Eli Lilly Stock: Analysts See 35% Upside, Driven by GLP-1 Demand and Q4 2025 ResultsNews and Statistics - IndexBox
What's going on with Eli Lilly on Monday? - MSN
Eli Lilly's diabetes drug cuts weight by 17% in trial - qz.com
Eli Lilly Weight Loss Push Weighs On Valuation And Growth Hopes - simplywall.st
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Lilly, Amgen Seek Fast Win in Suit Over Clinics in Discount Plan - Bloomberg Law News
Eli Lilly selects Lehigh Valley for $3.5 billion life sciences plant in 2026 - Lehigh Valley Business
What's Going On With Eli Lilly On Monday? - Benzinga
Eli Lilly (LLY) Faces Negative ROE Trend Despite Promising Future - GuruFocus
Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10 - TipRanks
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum - CNBC
0.51%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):